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POISON CENTRE RESEARCH
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ABSTRACT
Background: Bites by the European adder (Vipera berus) in the UK are uncommon but potentially life
threatening, and can be associated with marked limb swelling and disability. Following an interruption
in Zagreb Imunoloski zavod antivenom supply around 2012, the UK changed its national choice of
antivenom for Vipera berus to ViperaTAb, an ovine Fab monospecific antivenom. In the absence of
randomised controlled trials, we established an audit to review its use in clinical practice.
Methods: A prospective audit of ViperaTAb use was conducted from March 2016 until November
2020 by the UK National Poison Information Service (NPIS). Users of the NPIS online toxicology data-
base, TOXBASE, considering the use of antivenom for V. berus envenoming were invited to discuss the
case with the on-call clinical toxicology consultant. Information was collected prospectively on indica-
tions, administration, adverse reactions and outcome of patients administered ViperaTAb antivenom.
Results: One hundred and seventy patients were administered ViperaTAb antivenom over five years.
One hundred and thirty-two were adults and 38 children (median age and range: 38, 2–87 years). Bites
occurred across the UK, but most commonly in coastal regions of Wales and of South-West and East
England. Median time to presentation was 2.1 (IQR 1.5–4.0) h and to antivenom administration from
presentation was 2.0 (IQR 0.9–3.6) h. A minority of patients presented to hospital more than 12h after
being bitten (n¼ 19, 11.2%) or received antivenom more than 12h after presenting to hospital
(n¼ 17, 10.0%). Features of systemic envenoming were present in 64/170 (37.6%) patients, including
23 (13.5%) with anaphylaxis and 26 (15.3%) with hypotension (nine with both). Clinician assessment
considered the initial antivenom to have been effective in 122/169 (72.2%) patients. Repeated dosing
was common, occurring in 55/169 (32.5%), predominantly due to persisting or worsening local effects
(46/51, 90.2%). There were three cases of probable early adverse reaction. No deaths occurred during
the study. Complications of envenoming were rare but included four patients that underwent surgery,
three patients each with acute kidney injury, mild coagulopathy, or thrombocytopenia (one severe).
The median duration of hospital stay was 43.7 (IQR 22.5–66.5) h, longer for children than adults (52.5
vs 41.3 h).
Conclusion: ViperaTAb antivenom appears to be effective and safe and should be administered as
soon as possible for patients meeting clinical criteria. Patients require close observation following anti-
venom to detect adverse reactions and progression or recurrence of envenoming. Close collaboration
with expert NPIS consultant advice can help optimise antivenom timing, ensure repeated dosing is
given appropriately, and avoid unnecessary surgical intervention. All hospitals, particularly those
located in areas of relatively high incidence, should stock sufficient antivenom available at short
notice, 24 h a day.
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The European adder (Vipera berus) is the only species of
venomous snake native to the UK. Bites are uncommon
but potentially life-threatening, with an estimated 50–100
cases occurring annually in the UK [1,2]. Of these, 20–60
cases are treated with antivenom. Envenoming is
characterised by bite site pain, bruising, and swelling that
is often pronounced and may affect the entire limb and
trunk [3]. A minority of patients develop signs (or fea-
tures) of systemic envenoming, the most concerning of
which is a non-immune anaphylactic reaction to venom
which develops soon after the bite with angioedema,
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urticaria, hypotension and collapse. Other features of sys-
temic envenoming include vomiting, diarrhoea, and less
commonly cardiotoxicity, acute kidney injury, thrombo-
cytopaenia, and coagulopathy [3,4].
The Zagreb Imunoloski zavod antivenom, raised against
Croatian Vipera ammodytes venom [5] was used in the UK for
many years [1] before an interruption in production around
2012 [6]. This resulted in a change in choice of national anti-
venom from Zagreb to ViperaTAb (Micropharm) antivenom
for moderate-severe Vipera berus envenoming.
ViperaTAb is a monospecific ovine Fab antivenom raised
against whole V berus venom (sourced from Russia) manufac-
tured by MicroPharm Ltd, UK. Fab antigen binding com-
plexes are smaller than F(ab0)2 or whole IgG fragments
providing the theoretical advantage of enhanced tissue
penetration and fewer adverse reactions. However, the
increased volume of distribution and shorter half-life of Fab
fragments increases the risk of recurrent local and systemic
envenoming after antivenom administration [7]. Recurrent
venom antigenaemia with coagulopathy after treatment with
an Fab antivenom was first demonstrated in Echis ocellatus/
romani envenoming in Nigeria [8] and subsequently in a
comparative trial of Fab and F(ab0)2 antivenom for Crotalinae
envenoming in the USA [9].
As is the case for all antivenoms, the same initial dose of
ViperaTAb is given to children and adults. One dose consists
of two vials (8mL, 200mg), diluted in normal saline and
infused intravenously (IV) over 30min. The preclinical evalu-
ation and 50% binding value for ViperaTAb is superior to
that of Zagreb antivenom for V. berus venom [10].
There have been no randomised controlled trials of
ViperaTAb [5]. Published observational clinical data from 645
patients in Scandinavia, where ViperaTAb has been in use since
1991 [11–18], suggest efficacy with quick resolution in features
of envenoming, comparatively short length of hospital stay, and
fewer adverse reactions than with Zagreb antivenom [5,19].
Following the change in national antivenom supply, the
UK’s National Poison Information Service (NPIS) prospectively
audited the indications, administration, adverse reactions,
and outcomes of patients receiving ViperaTAb in the UK over
a period of five years.
Methods
A prospective audit was conducted by the NPIS, the UK’s
national poison control centre, of all V. berus snakebites from 1
March 2016 until the last case in 2020 (06 November 2020).
Records of calls to NPIS are routinely collected into a common
database, the UK Poisons Information Database (UKPID).
Clinicians accessing the UK toxicology database TOXBASE
for advice on the treatment of V. berus envenoming were
prompted with a Pop-Up box to telephone the NPIS and dis-
cuss management with the toxicology consultant on call if
they were considering antivenom. Demographic data and
envenoming details were routinely recorded during these
conversations. Advice on antivenom administration (per-
formed under close observation due to the possibility of
severe adverse reactions) was provided based on the clinical
criteria set out in TOXBASE (Box 1). Formal gradation was
not undertaken. Timing of bite, presentation to hospital, anti-
venom administration and discharge were used to ascertain
time to antivenom administration and length of hospital
stay. Follow-up telephone calls to support management were
made by one consultant. Clinicians were asked whether they
considered the antivenom to have been effective i.e.,
whether it resulted in rapid resolution of systemic features
and/or cessation in spread of local oedema and whether any
early adverse reactions had occurred.
Box 1. UK national guidelines for antivenom administration for Vipera
berus envenoming (TOXBASE, NPIS).
Antivenom should be given if the patient has any of the follow-
ing features:
1. Early anaphylaxis-like reactions to the venom.
2. Hypotension persisting for more than 10 minutes, with or with-
out features of shock.
3. Systemic features including abdominal pain or diarrhoea.
4. Definite leucocytosis (especially if over 20 × 109/l)
5. ECG abnormalities (e.g., bradycardia or widespread ischaemia)
6. Metabolic acidosis.
7. Elevated creatine kinase.
8. Severe local envenoming (even in the absence of systemic fea-
tures) i.e., swelling spreading beyond the next major joint.
9. Any other evidence of systemic envenoming e.g., spontaneous
haemorrhage, pulmonary oedema
Anonymous data were extracted from data recorded in
UKPID. Statistical analysis was performed on Graphpad Prism,
Version 8. Data were described using median and interquar-
tile range (IQR). Categorical data were compared using non-
parametric statistical tests with a p value of <0.05 consid-
ered significant.
This audit did not require approval by a UK Research
Ethics Committee as it used information collected routinely
as part of usual clinical care, with information provided for
analysis in a fully anonymized format.
Role of the funding source
The funders of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of the
report. The corresponding authors had full access to all the
data in the study and had final responsibility for the decision
to submit for publication.
Results
One hundred and seventy patients were identified as having
received ViperaTAb for snake envenoming during the study
period (average of 34 cases/year; range 31–40).
A further 57 cases (seven children) of envenoming who
presented to hospital (2 in 2016, 9 in 2017, 14 in 2018, 17 in
2019, 15 in 2020) and were discussed with NPIS did not
receive antivenom (because they had only mild local effects
not requiring antivenom [36/57, 63.2%], presented too late
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[usually after 48 h] [17/57, 29.8%], had an unclear diagnosis
on initial presentation [3/57, 5.3%]), or because antivenom
was not available [1/57. 1.8%]). Of note, five of the patients
presenting late, and one of the patients presenting with mild
envenoming, were adults who had had early systemic features
but had gone to bed rather than coming to hospital. They
presented after 1–3 days when their features of their systemic
envenoming had settled, and local signs did not require anti-
venom. These cases are not further discussed here.
Bite occurrence
Envenoming occurred predominantly over the summer
months with the first case on 26 February and the last case
on 06 November (Figure 1). Envenoming occurred most fre-
quently on weekends between the hours of 12:00 and
18:00 h (Figure 1).
Cases had a predominantly coastal distribution with clus-
ters occurring in West Wales and in South-West and East
England. Bites often occurred on coastal paths or beaches, or
in forests/heaths. The hospitals that treated most patients
with antivenom were located in Bangor (case n¼ 11),
Bournemouth/Poole (n¼ 11), Truro (n¼ 10), Swansea (n¼ 9)
and Exeter (n¼ 8) (Figure 2). Two patients were envenomed
in Sweden but travelled to the UK before seeking medical
attention. The snakes were not always seen, sometimes
delaying the presentation to hospital and/or the diagnosis.
Patients and clinical features on presentation
The median age of patients was 38.0 years (IQR 17.5–53.5)
with a male predominance (108 male, 62 female) (Figure 3).
There were 38 children (range 2–15 years), 13 of whom were
less than five years old.
There was a marked difference in bite site for women and
men. In men, 74 bites (68.5%) were on upper limbs, particu-
larly the right hand, while 33 (30.6%) occurred on the lower
limbs. By contrast, only ten (16.1%) occurred on the upper
limbs of women, while 51 (82.3%) occurred on the lower
limbs (p< 0.0001) (Figure 4). There was one bite on the face
and one bite on the abdomen.
Patients generally arrived quickly at hospital – median
time to presentation was 2.1 (IQR 1.5–4.0) h, although 19
cases (11.2%) presented to hospital more than 12 h after the
bite. At least four patients were transferred by air ambulance,
either from rural areas or from the west Scottish islands to
the mainland.
Figure 2. Location of hospitals treating envenomed patients.
Figure 1. Time of day (median and IQR), day of the week, and monthly distri-
bution of 170 bites requiring antivenom.
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All but two patients presented with localized swelling, with
or without pain. Twenty-three (13.5%, including two children)
presented with a non-immune anaphylactic reaction, attribut-
able directly to V. berus venom characterized by angioedema,
urticaria, and wheeze (Table 1). Twenty-six (15.3%, four children)
had hypotension, nine with other features of anaphylaxis and
17 without. Of the 41 patients with anaphylaxis and/or hypo-
tension, 11 required bolus intramuscular (IM) or IV adrenaline,
usually during transfer, before antivenom could be accessed.
Other features of systemic envenoming included vomiting (32)
and diarrhoea (14) (Table 1). A total of 64 patients (37.6%, 14
children) presented with systemic features. The incidence of
systemic features including anaphylaxis and hypotension was
similar for children, adults aged 16–64years old and adults
aged >64years old (Table 1).
Two patients were intubated and ventilated: due to
bronchospasm and hypoxia in an asthmatic adult while anti-
venom was being located and prepared, and due to airway
compromise following a facial bite to a child. Six patients
were noted to have transient ECG abnormalities attributed to
the envenoming (ST changes [2], left axis deviation [1], pro-
longed PR interval [1], prolonged QT interval [1] and unspeci-
fied abnormality [1]). Although laboratory values were not
systematically documented, leucocytosis and elevated D-
Dimer were commonly reported.
Antivenom administration
Median time to antivenom administration from admission was
2.0 (IQR 0.9–3.6) h – a median of 4.6 [2.8–9.4) h after the bite
(Figure 5). However, seventeen cases (10.0%) received their first
dose of antivenom more than 12h after presenting to hospital.
In six patients, antivenom was either delayed or staggered due
to insufficient antivenom stock at the initial hospital/health care
centre presentation. Envenoming progressed while in the hos-
pital for other patients, leading to the need for antivenom.
The appropriate initial dose of two vials (200mg) was
given to 168 patients. One patient, an 8-year-old girl,
received half a dose (1 vial) with the second vial adminis-
tered 5 h later; the second patient, a 45-year-old woman,
received half a dose (1 vial), responded sufficiently and did
not require further dosing. Of the 169 (99.4%) patients for
whom follow up was completed, 43 (25.4%) received one
additional dose and 12 (7.1%) received two additional doses.
Overall, 55/169 (32.5%) received additional antivenom dos-
ing, giving a total of 235 administrations.
The reason for repeated dosing of antivenom was identi-
fied for 51/55 patients. Persistent systemic features were
responsible in five patients (coagulopathy (n¼ 2), arrythmia
and cardiovascular instability (1), thrombocytopenia (1) and
hypotension (1)). Forty-six patients received additional
dose(s) due to worsening or persistent local effects (swelling,
less often haematoma, bite site necrosis). For just two
patients, the repeated dose was not clinically indicated
according to NPIS consultant review.
Median time to the second dose from the first dose was
15.2 (IQR 6.1–24.5, range 0.8–70.2) h and from presentation
was 16.7 (8.0–26.9, range 1.5–70.2) h (Figure 5). Patients
administered a second dose of antivenom for persistent or
worsening local envenoming <6 h after the first dose
(n¼ 16) had a shorter length of hospital stay (IQR 52.6
(47.1–69.0)) h than those who received a second dose >6 h
after the first dose (n¼ 29) (71.0 (46.9–98.4)) h (p¼ 0.08).
The latest a patient received antivenom was 67.0 h after
the bite and 47.5 h after presentation. The reasons for the
very late antivenom administrations (>36 h after the bite)
were delays to presentation to hospital (n¼ 3), misdiagnosis
as infection (1), initial discharge followed by evolution of
cytotoxicity (1) and self-discharge and re-presentation (1).
Assessment of effectiveness was attempted by asking
clinicians whether they considered the antivenom to have
been associated with improvement in their patients. They
deemed the initial antivenom to have been effective in 122/
169 patients (72.2%), generally with resolution of systemic
features and/or a rapid halt in the spread of swelling up the
limb. Nineteen of the 122 cases (15.6%) in which an initial
response was judged to have been favourable subsequently
required at least one additional dose of antivenom. One
patient required redosing of antivenom for systemic enve-
noming (hypotension), 6 h after the initial dose. The remain-
ing eighteen patients received an additional dose of
antivenom due to worsening or persistent local effects at a
median of time of 22.8 (IQR 7.1–29.1) h after the initial dose.
Safety of ViperaTAb
There were three cases of probable early adverse reactions to
antivenom: two of hypotension and one of urticaria tracking up
Figure 3. Age and sex distribution of cases.
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the line of the arm vein receiving the antivenom. The hypoten-
sion resolved without treatment while the patient with urticaria
was given adrenaline and hydrocortisone. Each of these
patients received the dose of antivenom in full and at least one
further dose of antivenom without reaction.
There were three possible early reactions to antivenom: one
case of worsening facial oedema (already present before anti-
venom therapy), one case of profuse diarrhoea, and one case
of abdominal pain and retching. Each resolved without spe-
cific therapy.
Three patients were noted to develop thrombocytopenia
(nadir platelet counts of 145, 88 and 5 109/L). The lowest
count occurred in a child with a platelet count of 35 on
admission, before antivenom administration. The first two
cases were managed conservatively without platelet infusion;
the final case was treated with 1 unit of platelets and two
Table 1. Systemic features related to age in patients envenomed by V berus subsequently treated with antivenom.
Children (0–15 years old) Adults 16–64 years old Adults> 64 years old Fisher exact between child/adult <65
Number of cases 38 119 13
Anaphylaxis 2 (5.3%) 20 (16.8%) 1 (7.7%) p¼ 0.11
Hypotension 4 (10.5%) 21 (17.6%) 1 (7.7%) p¼ 0.44
Diarrhoea 2 (5.3%) 11 (9.2%) 1 (7.7%) p¼ 0.73
Vomiting 11 (28.9%) 20 (16.8%) 1 (7.7%) p¼ 0.10
Any systemic feature(s) 14 (36.8%) 46 (38.6%) 4 (30.8%) p¼>0.99
NB. Each patient may have had more than one clinical feature of systemic envenoming.
Figure 4. Location of bites for women and men. Circle size is proportional to the number of bites at that site.
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further doses of antivenom as a decision was made that the
thrombocytopenia was likely due to the venom, and not
the antivenom.
Complications of envenoming
No deaths occurred during the study. Complications of enve-
noming are listed in Table 2. Four patients underwent surgery
(necrotic digital ulcers debridement [n¼ 2], incision and drain-
age of a haematoma in a patient on an anticoagulant when
envenomed [1], and fasciotomy for suspected compartment
syndrome (healthy muscle was found at operation) [1]). Five
developed metabolic acidosis, three acute kidney injury, three
mildly deranged clotting function, and two mild transaminitis.
Two patients were noted to have microscopic haematuria on
dipstick urinalysis, while three (noted above) had thrombocyto-
penia that may have been due to venom. All laboratory abnor-
malities improved prior to discharge from hospital.
Length of hospital stay
Median duration of hospital stay (n¼ 169, 99.4%) was 43.7
(IQR 22.5–66.5) h. It was longer for patients aged >64 yrs
(67.2 [IQR 26.2–122.3] h), compared to children aged <16 yrs
(52.5 [IQR 39.4–91.0] h), and adults aged 16–64 years old
(38.8 [IQR 20.7–53.3] h) (Kruskal–Wallis p¼ 0.004) (Figure 6).
Eight patients remained in hospital for seven or more
days (Figure 6). The reasons for these prolonged admissions
were rehabilitation due to extensive local effects (n¼ 4), sus-
pected compartment syndrome managed conservatively (2),
incision and drainage of haematoma formed at the bite site
in a patient on rivaroxaban (1), and fasciotomy for suspected
compartment syndrome (1).
Table 3 presents five cases of envenoming that illustrate a
spectrum of severe local and systemic envenoming, the
importance of early antivenom and importance of compart-
mental pressure assessment. The inappropriate prioritisation
of surgical assessment over antivenom therapy was observed
in several patients.
Discussion
This prospective study of ViperaTAb supports Scandinavian
experience that the antivenom is safe and appears effective
for V. berus envenoming. The median length of hospital stay
(a useful marker of antivenom efficacy given the
predominant local effects of envenoming) of 43.7 h was simi-
lar to that in a study of V. berus and Vipera aspis bites
treated with a French viper antivenom, ViperFAV, and shorter
Table 2. Effects and complications of envenoming in
patients treated with antivenom.
Clinical complication Frequency
Bite site ischaemia/necrosis 9 (5.3%)
Blister/bullae 3 (1.8%)
ECG abnormalities 6 (3.5%)
Rash 6 (3.5%)
Blister/bullae 3 (1.8%)
DVT (confirmed by USS doppler) 1 (0.6%)
Figure 6. Length of hospital stay for children (<16 years old), adults
(16–64 years old) and adults (>64years old). Five values lie outside of the limit
of the Y-axis (Children <16 years = 212h, Adults (16-64 years) = 242 h, 254 h
and 261 h and Adult (>64 years) = 406 h)
Figure 5. Time (median and IQR) to presentation, first and second dose of antivenom.
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than reported for cases receiving the Zagreb anti-
venom [5,19,20].
Patients requiring antivenom typically presented to hos-
pital, were assessed, and received antivenom in a timely
manner, often within 4 h of the bite. However, there were
delays in presentation and antivenom administration in a
few cases. Delays to antivenom after arrival at hospital were
sometimes explained by evolving clinical features. However,
on other occasions antivenom was delayed due to the lim-
ited experience of the clinicians involved, with a sense that
orthopaedic review rather than antivenom was the priority.
There were delays to antivenom administration in six
patients due to limited stock at the presenting hospital.
Delays to antivenom therapy for V. berus and V. aspis enve-
noming has been found to be associated with increased risk
of haematoma formation and prolonged functional impair-
ment [21,22].
Seventeen patients delayed their presentation to hospital
until it was considered too late (after 48 h) for benefit from
antivenom. Scanning of newspaper articles revealed other
patients who chose to not attend hospital, with clear conse-
quences for the functional status over the coming weeks




Time to discharge from
presentation (h) Illustrative point Clinical details
1 21.0 and 66.9 254 Importance of
early antivenom.
A female patient developed a sharp pain on her foot whilst
walking (unwitnessed bite). She presented to hospital with a
diffusely tender, swollen leg, leucocytosis (25 103/mL) and
metabolic acidosis. Snakebite was considered as a differential
diagnosis in the emergency department; however, the
patient was given IV antibiotics and referred to orthopaedics
for assessment of possible necrotizing fasciitis and/or
compartment syndrome. No surgical intervention was
required. Antivenom was administered 17.5 h after
presentation resulting in an improvement in clinical features
and biochemistry; however, due to the substantial local
effects, the patient required a prolonged period of
rehabilitation.
2 4.8 212.7 Importance of compartmental
pressure assessment.
A male child presented following a bite to the right foot.
Antivenom was given for local effects with no evidence of
systemic features. It was adjudged to have been effective
and no further doses were administered. The following day,
further swelling of the affected limb was noted. He
underwent fasciotomy for suspected compartment syndrome
without prior radiological or compartmental pressure
assessment. In theatre, the muscle was found to be swollen
but pink and healthy.





Following a bite to the left hand, a male patient presented
with perioral paraesthesiae, lip swelling, a sensation of “tight
throat” and swelling to the elbow. He was administered IM
adrenaline and ViperaTAb, resulting in resolution of systemic
features. Over the next 24 h, oedema progressed to the
upper arm and onto the thorax despite a further dose of
antivenom. Due to clinical concern about compartment
syndrome, compartmental pressures were measured and
found to be normal (9–10mmHg). He received a final (third)
dose of ViperaTAb and gradually improved with
conservative management.




A male child presented 3.4 h after sustaining a bite on the right
ankle in a rural area. At presentation he was lethargic,
complained of abdominal pain, and had ST changes and
sinus tachycardia on ECG. Adrenaline and fluids were given
as urgent treatment in the emergency department. Bloods
revealed a thrombocytopenia (35 109/ L), raised lactate
(2.3mmol/ L) and metabolic acidosis (pH 7.32). Despite
delays due to a lack of antivenom stock at the hospital, his
symptoms improved following antivenom administration. The
following day the thrombocytopenia had worsened and
remained low for a further five days (nadir of 5 109/ L).
Two further doses of antivenom and 1 unit of platelets were
administered and the patient observed until sustained
improvement in platelets count (80 109/ L at discharge).
5 3.2 and 5.7 67.3 Severe systemic envenoming.
Importance of rapid
assessment and treatment.
Within 15min of a bite to his right hand, the male patient
vomited, felt unwell, became drowsy and experienced
swelling of his mouth and throat. He was treated at the
scene with IM adrenaline before transfer to hospital by air
ambulance. Antivenom was administered within 30min of
presentation to hospital. Following antivenom, systemic
features resolved. A second dose of antivenom was
administered for progressive swelling to the envenomed
limb. The patient made a good recovery and was discharged
2 days later.
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and months [23]. Unfortunately, a radio and newspaper cam-
paign in 2017 [24,25] failed to reduce the number of people
presenting late to hospital.
The frequency of repeated dosing of ViperaTAb in this
study (33.1%) is greater than previously reported in two
large case series in Sweden (15.7% and 20.0%) [11,17] and
a systematic review of all European antivenom (15.8%) [5].
This may be because of frequent contact between poison
centre staff and clinicians looking after the patients, with
careful discussion about need for additional antivenom. The
common indication for repeated doses in this study was
persistence or worsening of local envenoming, in particular
swelling and increasing pain. On several occasions, clear
benefit became apparent shortly after antivenom adminis-
tration. This is supported by the shorter length of hospital
duration for patients administered early (<6 h) repeated
dosing of antivenom for persistent or increasing local enve-
noming and the illustrative cases 1 and 5 in Table 3.
However, several French papers on V. berus and V. aspis
envenoming report limited beneficial effect on local
oedema and no reduction in length of hospital stay for
patients administered multiple doses of ViperFAV for per-
sisting oedema [20–22]. As a result, the practice of repeated
dosing is reserved for patients with increasing Audebert
envenoming severity score [26] or recrudescence of clinical
features, following advice from French Poison Control
Centres [20].
The need for repeated antivenom dosing because of per-
sisting/recurrent systemic envenoming was uncommon in
this study (only 2.9%), similar to that for patients treated
with ViperaTAb by the Swedish Poisons information Service
(13/415, 3.1%) [17]. This contrasts with a French study which
showed that 4/23 (17.4%) and 7/64 (10.9%) of patients with
V. berus and V. aspis envenoming, respectively, treated with
ViperaTAb developed persisting systemic envenoming after
the initial dose of antivenom [20]. This apparent difference in
effectiveness between UK/Scandinavia and France warrants
further investigation. A comparative randomized control trial
would help determine comparative effectiveness and the
clinical implications of Fab and F(ab0)2 pharmacokinetics in
Vipera genera envenoming [9,27].
Despite promising in vitro cross-reactivity of ViperaTAb
across the Vipera genus [10], further evidence is required to
demonstrate clinical effectiveness, especially in light of its
relatively poor performance against Vipera ammodytes enve-
noming [23]. Both ViperaTAb and ViperFAV antivenoms are
manufactured using V. berus venom sourced from Russia (Ian
Cameron, personal communication). Consequently, the possi-
bility of intraspecies geographical variation in venom com-
position should be considered as this might cause variable
effectiveness of antivenom in different geographical locations
[28,29].
ViperaTAb was well tolerated, with only three probable
and three possible adverse reactions detected. With the
exception of one patient who was treated cautiously with
adrenaline and corticosteroids, the reported adverse reac-
tions resolved spontaneously. Four of the six patients went
on to receive a further dose of antivenom without any
additional reaction. The lack of recurrent adverse reactions in
repeatedly dosed individuals is suggestive of an alternative
mechanism to classical Type-1 IgE mediated hypersensitivity
[30]. In addition, it supports the advice that intradermal test-
ing should not be used to predict patients susceptible to
adverse reactions to antivenom [31]. It seems likely that the
three observed cases of thrombocytopenia, in one case
before antivenom treatment and in two cases after anti-
venom treatment, represent a manifestation of envenoming
as commonly described in literature rather than an adverse
reaction to antivenom [3,12,22].
Although rare, the pronounced early anaphylactic reaction
to venom is a medical emergency and necessitates immedi-
ate management with adrenaline while antivenom is pre-
pared. In this cohort, all 23 patients with early anaphylactic
reactions – some of whom required multiple doses of adren-
aline – responded to antivenom with rapid resolution of
symptoms. In one patient, angioedema returned following
antivenom administration and a further dose of antivenom
was given with good effect. The frequency of systemic fea-
tures of envenoming was similar for children, adults, and
older adults aged >64 yrs, consistent with previous reports
of V. berus and V. aspis envenoming [21,22]. Despite this,
children more frequently received multiple dosing of anti-
venom and had modestly longer durations of hospital stay.
One possible explanation of this discrepancy is that children
experience greater bite site cytotoxicity with more pro-
nounced oedema and haematoma formation due to their
higher venom dose per body weight [21].
Four patients underwent surgery during their hospital
admission resulting in an increased length of hospital stay
(median of 6 days). One case underwent a fasciotomy with-
out prior assessment of compartmental pressure (Table 3).
The resulting surgery revealed healthy muscle. A further case
was due to undergo imminent fasciotomy before advice to
reconsider altered the plan and a conservative approach was
taken. The patient with severe local envenoming with
marked oedema of the thorax, after a bite on the hand, was
effectively treated with antivenom only, after measurement
of compartmental pressures showed normal pressures (Table
3). Local cytotoxicity from V. berus envenoming can result in
marked soft tissue oedema but seldom if ever results in com-
partment syndrome. Both ultrasound and compartmental
pressure assessment have been strongly advocated to distin-
guish extra fascial from subfascial oedema, thus limiting sur-
gical intervention where possible [32–34].
There was marked gender difference in bite site location,
with male subjects more likely to be bitten on the upper
limbs, especially on their hands (Figure 5), and females more
likely to be bitten on the lower limbs. This tendency was
also observed in snakebites in the USA, where 56% of bites
in males were on the upper extremity, and 67% resulted
from handling the snake [35]. Unlike many tropical countries
where envenoming is associated with agricultural work,
envenoming in the UK typically occurs during leisure activ-
ities. As a result, a significant number of upper limbs bites
resulted from deliberate interaction with the snake and
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demonstrates the need for educational messaging, especially
to men, to prevent such envenoming in future.
Limitations
The rarity of adder bite and envenoming in the UK necessi-
tates the use of national poison centre records for prospect-
ive data collection. Efforts were made to overcome the
inherent limitations of this method by using single caller fol-
low up of cases and objective assessments of outcome (dur-
ation of hospital stay, adverse events and need for recurrent
antivenom administration) in addition to an independent
subjective assessment of effectiveness by the attending clin-
ician. However, limitations are acknowledged with incom-
plete data collection for three patients, a lack of systematic
collection of laboratory findings, a lack of comprehensive
ancillary medications used, and no routine follow up
arranged after discharge.
Conclusion
V. berus bites necessitating antivenom use are rare but
remain a potentially life-threatening emergency in some
circumstances as shown by the occasional need for adren-
aline or intubation. ViperaTAb antivenom appears to be
effective and safe and should be administered as soon as
possible for patients meeting clinical criteria outlined in
Box 1. Patients require close observation following anti-
venom for adverse reactions and recrudescence of swel-
ling and pain in the limbs. Close collaboration with expert
consultant advice from the NPIS can help optimise anti-
venom timing, ensure repeated dosing is given appropri-
ately, and avoid unnecessary surgical intervention. All
hospitals, particularly those located in areas of relatively
high incidence, should stock sufficient antivenom avail-
able at short notice, 24 h a day. Increased community
awareness of the dangers of snake handling may help
avoid some unnecessary upper limb bites.
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